Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials in Seattle, Washington

4 studies are recruiting for pancreatic ductal adenocarcinoma (pdac) in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Washington Fred Hutchinson Cancer Center, Seattle, Washington
    Locations
    48 in total
    Run by
    Immuneering Corporation

    See if you can join NCT07562152 on ClinicalTrials.gov

  2. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Virginia Mason Medical Center, Seattle, Washington
    Locations
    49 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07491445 on ClinicalTrials.gov

  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Virginia Mason, Seattle, Washington
    Locations
    29 in total
    Run by
    Verastem, Inc.

    See if you can join NCT07644559 on ClinicalTrials.gov

  4. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Virginia Mason Medical Center, Seattle, Washington
    Locations
    21 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.